Pre-order Enquiry
Request Free Sample
Global Anthrax Vaccines Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
SKU ID : GIR-13851273 | Publishing Date : 14-Feb-2019 | No. of pages : 139
Request Sample
Request Customization
Check Discounts
Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.
Scope of the Report:
The classification of Anthrax Vaccines includes Live Vaccines and Cell free PA Vaccines, and the revenue proportion of Live Vaccines in 2016 is about 43%.
Anthrax Vaccines are widely used for human and animal. The most proportion of Anthrax Vaccines is used for animal, and the consumption proportion is about 95.1% in 2016.
South America region is the largest supplier of Anthrax Vaccines, with a production market share nearly 34.7% in 2016. Europe is the second largest supplier of Anthrax Vaccines, enjoying production market share nearly 17.6% in 2016.
South America is the largest sales place, with a sales market share nearly 39.3% in 2016. Following South America, Europe is the second largest sales place with the sales market share of 19.1%.
Along with the development of China 's Agricultural technology, there is a lot Chinese local manufacturer can produce Anthrax Vaccines, with the increasing demand, more and more manufactures will go into Anthrax Vaccines industry.
Market competition is intense. Emergent BioSolutions is the major manufacturer of Anthrax Vaccines used for human, Merial, Merck, Zoetis, Bayer Sanidad Animal,Colorado Serum, etc. are is the major manufacturer of Anthrax Vaccines used for animal, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Anthrax Vaccines is expected to grow at a CAGR of roughly 7.5% over the next five years, will reach 720 million US$ in 2024, from 500 million US$ in 2019, according to a new study.
This report focuses on the Anthrax Vaccines in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Emergent BioSolutions
Merial
Merck
Zoetis
Bayer Sanidad Animal
Colorado Serum
PharmAthene
Tiankang
Biogénesis-Bago
CAVAC
Rosenbusch
Agrovet
Vecol
CVCRI
IVPM
Prondil
CDV
Indian Immunologicals
Botswana Vaccine Institute
Ceva Santé Animale
Intervac
JOVAC
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Live Vaccines
Cell free PA Vaccines
Market Segment by Applications, can be divided into
Human Use
Animal Use
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Anthrax Vaccines product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Anthrax Vaccines, with price, sales, revenue and global market share of Anthrax Vaccines in 2017 and 2018.
Chapter 3, the Anthrax Vaccines competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anthrax Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Anthrax Vaccines market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Anthrax Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Scope of the Report:
The classification of Anthrax Vaccines includes Live Vaccines and Cell free PA Vaccines, and the revenue proportion of Live Vaccines in 2016 is about 43%.
Anthrax Vaccines are widely used for human and animal. The most proportion of Anthrax Vaccines is used for animal, and the consumption proportion is about 95.1% in 2016.
South America region is the largest supplier of Anthrax Vaccines, with a production market share nearly 34.7% in 2016. Europe is the second largest supplier of Anthrax Vaccines, enjoying production market share nearly 17.6% in 2016.
South America is the largest sales place, with a sales market share nearly 39.3% in 2016. Following South America, Europe is the second largest sales place with the sales market share of 19.1%.
Along with the development of China 's Agricultural technology, there is a lot Chinese local manufacturer can produce Anthrax Vaccines, with the increasing demand, more and more manufactures will go into Anthrax Vaccines industry.
Market competition is intense. Emergent BioSolutions is the major manufacturer of Anthrax Vaccines used for human, Merial, Merck, Zoetis, Bayer Sanidad Animal,Colorado Serum, etc. are is the major manufacturer of Anthrax Vaccines used for animal, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Anthrax Vaccines is expected to grow at a CAGR of roughly 7.5% over the next five years, will reach 720 million US$ in 2024, from 500 million US$ in 2019, according to a new study.
This report focuses on the Anthrax Vaccines in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Emergent BioSolutions
Merial
Merck
Zoetis
Bayer Sanidad Animal
Colorado Serum
PharmAthene
Tiankang
Biogénesis-Bago
CAVAC
Rosenbusch
Agrovet
Vecol
CVCRI
IVPM
Prondil
CDV
Indian Immunologicals
Botswana Vaccine Institute
Ceva Santé Animale
Intervac
JOVAC
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Live Vaccines
Cell free PA Vaccines
Market Segment by Applications, can be divided into
Human Use
Animal Use
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Anthrax Vaccines product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Anthrax Vaccines, with price, sales, revenue and global market share of Anthrax Vaccines in 2017 and 2018.
Chapter 3, the Anthrax Vaccines competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anthrax Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Anthrax Vaccines market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Anthrax Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
